Cutaneous Lupus Erythematosus (CLE)

Overview

Cutaneous Lupus Erythematosus (CLE) is an autoimmune skin disorder in which the immune system attacks healthy skin cells, causing inflammation and characteristic rashes. CLE can occur on its own (isolated cutaneous lupus) or as part of systemic lupus erythematosus (SLE). The most common subtypes are:

• Discoid lupus erythematosus (DLE) – well‑defined, disc‑shaped plaques that can scar.
• Subacute cutaneous lupus erythematosus (SCLE) – red‑purple, scaly lesions that often appear on sun‑exposed areas.
• Acute cutaneous lupus erythematosus (ACLE) – the classic “butterfly” rash over the cheeks and nose, usually linked to systemic disease.

CLE affects roughly 5–10 % of people with lupus and can appear at any age, but it most often begins in the 20s–40s. Sun exposure, genetics, and hormonal factors play key roles in disease development. [1][2]

Symptoms Checklist

Check any symptoms you are experiencing. If several are present, especially after sun exposure, consult a dermatologist.

• ☐ Red, raised, scaly patches (often on the face, scalp, ears, or neck)
• ☐ Discoid plaques with a raised border and central scarring
• ☐ “Butterfly” rash across the cheeks and bridge of the nose
• ☐ Itchy or painful lesions that worsen after sun exposure (photosensitivity)
• ☐ Darkening or hyperpigmentation of healed lesions
• ☐ Hair loss (alopecia) in areas of scalp involvement
• ☐ Mouth or nose ulcers (less common in isolated CLE)
• ☐ Joint pain or fatigue (may suggest systemic involvement)

Sources: Mayo Clinic, CDC, NIH.

Risk Factors

• Female gender (≈ 90 % of cases) – estrogen may influence immune activity.
• Age 20–40 years, though CLE can appear at any age.
• Family history of lupus or other autoimmune diseases.
• Genetic predisposition (certain HLA types, e.g., HLA‑DR2, HLA‑DR3).
• Excessive ultraviolet (UV) light exposure – natural sunlight or tanning beds.
• Smoking – increases risk of disease flares and reduces response to therapy.
• Certain medications that can trigger lupus‑like skin reactions (e.g., procainamide, hydralazine).

Sources: Cleveland Clinic, Johns Hopkins.

Diagnosis

Diagnosing CLE involves a combination of clinical evaluation, laboratory testing, and skin biopsy.

1. Clinical examination – Dermatologist assesses lesion morphology, distribution, and photosensitivity.
2. Skin biopsy – Histopathology shows interface dermatitis, basal keratinocyte vacuolization, and deposition of immunoglobulins (positive “lupus band test”).
3. Blood tests – Antinuclear antibody (ANA) panel, anti‑Ro/SSA, anti‑La/SSB, and complement levels help differentiate cutaneous‑only disease from systemic lupus.
4. Phototesting – May be performed to confirm photosensitivity.
5. Imaging – Not routinely required for isolated CLE, but chest X‑ray or echocardiogram may be ordered if systemic involvement is suspected.

Sources: Mayo Clinic, NIH.

Treatment Options

Therapy is individualized based on disease severity, subtype, and patient preferences.

Medical Treatments

• Topical corticosteroids – First‑line for mild lesions; potency selected according to location.
• Topical calcineurin inhibitors (tacrolimus, pimecrolimus) – Useful for facial or delicate‑area lesions to avoid steroid‑induced atrophy.
• Antimalarial drugs – Hydroxychloroquine (Plaquenil) is the cornerstone for moderate‑to‑severe CLE; dosing is weight‑based and requires baseline retinal screening. [3]
• Systemic immunosuppressants – Methotrexate, mycophenolate mofetil, azathioprine, or low‑dose systemic steroids for refractory disease.
• Biologic agents – Belimumab or rituximab may be considered in patients with concurrent systemic lupus or refractory cutaneous disease.
• Retinoids – Acitretin can be used for resistant discoid lesions, but teratogenicity must be considered.

Home & Lifestyle Treatments

• Broad‑spectrum sunscreen (SPF ≥ 30) applied 15 minutes before sun exposure; reapply every 2 hours.
• Protective clothing, wide‑brim hats, and UV‑blocking sunglasses.
• Avoid tanning beds and peak sun hours (10 am–4 pm).
• Smoking cessation – improves treatment response.
• Gentle skin care: fragrance‑free moisturizers, lukewarm water, and avoidance of harsh scrubs.
• Stress‑reduction techniques (mindfulness, yoga) – stress can exacerbate flares.

Sources: CDC, Cleveland Clinic, Johns Hopkins.

Prevention

While CLE cannot be completely prevented, risk can be markedly reduced:

• Consistent daily use of high‑SPF sunscreen and sun‑protective clothing.
• Regular dermatology follow‑up for early detection of new lesions.
• Quit smoking and limit alcohol intake.
• Maintain a healthy weight and balanced diet rich in antioxidants (fruits, vegetables, omega‑3 fatty acids).
• Review medication list with your physician; avoid drugs known to trigger lupus‑like rashes.

Living With Cutaneous Lupus Erythematosus

• Skin monitoring – Perform a weekly “skin check” to note new or changing lesions.
• Medication adherence – Take antimalarials exactly as prescribed; schedule annual eye exams for hydroxychloroquine.
• Sun‑smart habits – Keep a sunscreen bottle in your bag, car, and at work.
• Support networks – Join lupus support groups (e.g., Lupus Foundation of America) for emotional support and practical tips.
• Work & school accommodations – Request flexible indoor lighting or indoor workspaces during flare‑prone seasons.
• Psychological wellbeing – Consider counseling if chronic disease impacts mood or self‑image.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe facial swelling or difficulty breathing (possible anaphylaxis to medication).
• Rapidly spreading rash accompanied by fever, chills, or joint pain (possible systemic flare).
• Severe chest pain, shortness of breath, or palpitations (could indicate cardiac involvement).
• Acute visual changes or eye pain (hydroxychloroquine retinal toxicity is rare but urgent).
• Unexplained severe headache, confusion, or seizures (possible central nervous system involvement).

References

1. Mayo Clinic. “Cutaneous lupus erythematosus.” https://www.mayoclinic.org
2. Centers for Disease Control and Prevention (CDC). “Lupus (Systemic Lupus Erythematosus).” https://www.cdc.gov
3. National Institutes of Health (NIH) – National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Hydroxychloroquine for Lupus.” https://www.niams.nih.gov
4. Cleveland Clinic. “Cutaneous Lupus Erythematosus (Skin Lupus).” https://my.clevelandclinic.org
5. Johns Hopkins Medicine. “Lupus – Skin Manifestations.” https://www.hopkinsmedicine.org